• 1
    Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C, Aranda S. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 2008; 26: 561829.
  • 2
    Cline BW. Prevention of chemotherapy-induced alopecia: a review of the literature. Cancer Nurs 1984; 7: 2218.
  • 3
    Dorr VJ. A practitioner's guide to cancer-related alopecia. Semin Oncol 1998; 25: 56270.
  • 4
    Botchkarev VA. Molecular mechanisms of chemotherapy-induced hair loss. J Investig Dermatol Symp Proc 2003; 8: 725.
  • 5
    Grevelman EG, Breed WP. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 2005; 16: 3528.
  • 6
    Christodoulou C, Tsakalos G, Galani E, Skarlos DV. Scalp metastases and scalp cooling for chemotherapy-induced alopecia prevention. Ann Oncol 2006; 17: 350.
  • 7
    Jimenez JJ, Roberts SM, Mejia J, Mauro LM, Munson JW, Elgart GW, Connelly EA, Chen Q, Zou J, Goldenberg C, Voellmy R. Prevention of chemotherapy-induced alopecia in rodent models. Cell Stress Chaperones 2008; 13: 318.
  • 8
    Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 2004; 12: 5439.
  • 9
    Wang J, Lu Z, Au JL. Protection against chemotherapy-induced alopecia. Pharm Res 2006; 23: 250514.
  • 10
    Schilli MB, Paus R, Menrad A. Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol-analogs. J Invest Dermatol 1998; 111: 598604.
  • 11
    Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe RT, Jr, Griffin RJ, Harris PA, et al. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001; 291: 1347.
  • 12
    Paus R, Handjiski B, Eichmuller S, Czarnetzki BM. Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. Am J Pathol 1994; 144: 71934.
  • 13
    Danks JA, Ebeling PR, Hayman J, Chou ST, Moseley JM, Dunlop J, Kemp BE, Martin TJ. Parathyroid hormone-related protein: immunohistochemical localization in cancers and in normal skin. J Bone Miner Res 1989; 4: 2738.
  • 14
    Lee K, Deeds JD, Segre GV. Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acids during fetal development of rats. Endocrinology 1995; 136: 45363.
  • 15
    Shin JH, Ji C, Casinghino S, McCarthy TL, Centrella M. Parathyroid hormone-related protein enhances insulin-like growth factor-I expression by fetal rat dermal fibroblasts. J Biol Chem 1997; 272: 23498502.
  • 16
    Orloff JJ, Wu TL, Stewart AF. Parathyroid hormone-like proteins: biochemical responses and receptor interactions. Endocr Rev 1989; 10: 47695.
  • 17
    Holick MF, Ray S, Chen TC, Tian X, Persons KS. A parathyroid hormone antagonist stimulates epidermal proliferation and hair growth in mice. Proc Natl Acad Sci USA 1994; 91: 80146.
  • 18
    Peters EM, Foitzik K, Paus R, Ray S, Holick MF. A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist. J Invest Dermatol 2001; 117: 1738.
  • 19
    Safer JD, Ray S, Holick MF. A topical parathyroid hormone/parathyroid hormone-related peptide receptor antagonist stimulates hair growth in mice. Endocrinology 2007; 148: 116770.
  • 20
    Matsushita O, Jung CM, Minami J, Katayama S, Nishi N, Okabe A. A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase. J Biol Chem 1998; 273: 36438.
  • 21
    Chorev M. Parathyroid hormone 1 receptor: insights into structure and function. Receptors Channels 2002; 8: 21942.
  • 22
    Gensure RC, Gardella TJ, Juppner H. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 2005; 328: 66678.
  • 23
    Jonsson KB, John MR, Gensure RC, Gardella TJ, Juppner H. Tuberoinfundibular peptide 39 binds to the parathyroid hormone (PTH)/PTH-related peptide receptor, but functions as an antagonist. Endocrinology 2001; 142: 7049.
  • 24
    Maretto S, Schievano E, Mammi S, Bisello A, Nakamoto C, Rosenblatt M, Chorev M, Peggion E. Conformational studies of a potent Leu11,D-Trp12-containing lactam-bridged parathyroid hormone-related protein-derived antagonist. J Pept Res 1998; 52: 2418.
  • 25
    Bergwitz C, Jusseaume SA, Luck MD, Juppner H, Gardella TJ. Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH)-2 receptor determine signaling selectivity for PTH and PTH-related peptide. J Biol Chem 1997; 272: 288618.
  • 26
    Tamai E, Ishida T, Miyata S, Matsushita O, Suda H, Kobayashi S, Sonobe H, Okabe A. Accumulation of Clostridium perfringens epsilon-toxin in the mouse kidney and its possible biological significance. Infect Immun 2003; 71: 53715.
  • 27
    Shimamoto S, Tamai E, Matsushita O, Minami J, Okabe A, Miyata S. Changes in ganglioside content affect the binding of Clostridium perfringens epsilon-toxin to detergent-resistant membranes of Madin-Darby canine kidney cells. Microbiol Immunol 2005; 49: 24553.
  • 28
    Paus R, Schilli MB, Handjiski B, Menrad A, Henz BM, Plonka P. Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res 1996; 56: 443843.
  • 29
    Tobin DJ, Hagen E, Botchkarev VA, Paus R. Do hair bulb melanocytes undergo apoptosis during hair follicle regression (catagen)? J Invest Dermatol 1998; 111: 9417.
  • 30
    Muller-Rover S, Handjiski B, van der Veen C, Eichmuller S, Foitzik K, McKay IA, Stenn KS, Paus R. A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol 2001; 117: 315.
  • 31
    Katikaneni R, Ponnapakkam A, Miller E, Ponnapakkam T, Gensure RC. A new technique for precisely and accurately measuring lumbar spine bone mineral density in mice using clinical dual energy X-ray absorptiometry (DXA). Toxicol Mech Methods 2009; 19: 22531.
  • 32
    Ponnapakkam T, Matsushita O, Sakon J, Gensure RC. Weekly administration of a novel parathyroid hormone-collagen binding domain fusion protein increases bone mineral density by more than 15% in normal mice. American Society for Bone and Mineral Research (ASBMR), 2025 M Street, NW, Suite 800, Washington DC 20036-3309, 2007.
  • 33
    Carter PH, Juppner H, Gardella TJ. Studies of the N-terminal region of a parathyroid hormone-related peptide (1–36) analog: receptor subtype-selective agonists, antagonists, and photochemical cross-linking agents. Endocrinology 1999; 140: 497281.
  • 34
    Hirbe A, Morgan EA, Uluckan O, Weilbaecher K. Skeletal complications of breast cancer therapies. Clin Cancer Res 2006; 12: 6309s14s.
  • 35
    Kim SH, Lim SK, Hahn JS. Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy. Am J Med 2004; 116: 5248.
  • 36
    Barbehenn EK, Lurie P, Wolfe SM. Osteosarcoma risk in rats using PTH 1–34. Trends Endocrinol Metab 2001; 12: 383.
  • 37
    Rosenblatt M, Potts JT, Jr. Analogues of an in-vitro parathyroid hormone inhibitor: modifications at the amino terminus. Calcif Tissue Int 1981; 33: 1537.
  • 38
    Carter PH, Petroni BD, Gensure RC, Schipani E, Potts JT, Jr., Gardella TJ. Selective and nonselective inverse agonists for constitutively active type-1 parathyroid hormone receptors: evidence for altered receptor conformations. Endocrinology 2001; 142: 153445.
  • 39
    Tosi A, Misciali C, Piraccini BM, Peluso AM, Bardazzi F. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf 1994; 10: 3107.
  • 40
    Nakashima-Kamimura N, Nishimaki K, Mori T, Asoh S, Ohta S. Prevention of chemotherapy-induced alopecia by the anti-death FNK protein. Life Sci 2008; 82: 21825.